Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy

  • STATUS
    Recruiting
  • End date
    Jan 29, 2029
  • participants needed
    194
  • sponsor
    Gencurix, Inc.
Send
Updated on 19 February 2024
See if I qualify

Summary

A prospective, randomized, comparative study to evaluate efficacy of anticancer chemotherapy in predicting prognosis and determining chemotherapy method in early Hormone Receptor-positive breast cancer patients with clinicopathological high risk and GenesWell BCT low risk at multi-center in Korea

Details
Condition Early Hormone Receptor-positive Breast Cancer
Age 19-80 years
Treatment Chemotherapy Drugs, Cancer
Clinical Study IdentifierNCT04278469
SponsorGencurix, Inc.
Last Modified on19 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Adult women aged 19-80 at screening
Histologically invasive carcinoma
Hormone receptor positive (Estrogen, ER+ and/or Progesterone, PR+)
Human epidermal growth factor receptor 2 negative (HER2-)
Axillary lymph node assessment: pN0 or pN1
Tumor size0.5cm
Clinical high risk (based on modified Adjuvant! Online)
Patients who agree to genetic testing
Patients who have adequate organ function
Genomic low risk (based on GenesWell BCT)
De novo primary cancer
Patients how performed surgery with curative aim
Patients who have provided written informed consent themselves

Exclusion Criteria

Hormone receptor negative (Estrogen, ER- and Progesterone, PR-)
Human epidermal growth factor receptor 2 positive (HER2+)
Axillary lymph node assessment: pN2 or pN3
Patients who are received chemotherapy prior to operation
Patients who are received radiotherapy prior to operation
Tumor size<0.5cm
Clinical low risk
FFPE tumor sample is not available
Patients with following conditions
Patient with chronic liver disease
Patient with cerebrovascular disease
Patient with chronic mental disorder
Pregnant women, women of childbearing potential or lactating women
Patients who are deemed inappropriate as study participants by investigators
Patients with recurrent breast cancer or treatment history of breast cancer
Patients who have not undergone surgery
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.